Cytochrome C

Attruby (acoramidis) is an oral prescription medicine used to treat heart problems due to cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). Attruby works by stabilizing transthyretin (TTR) to help reduce death and cardiovascular-related hospitalization and improve quality of life. Attruby mechanism of action is by binding to TTR at thyroxine binding sites, which slows the formation of harmful amyloid protein deposits in the heart, slowing disease progression. Attruby (acoramidis) is a near-complete (≥90%)  selective stabilizer of transthyretin (TTR), Attruby FDA approval was granted on November 22, 2024, it is indicated for treating the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular-related hospitalization and death. Attruby FDA approval was based on positive results from the ATTRibute-CM Phase 3 study, which showed a statistically significant treatment effect at 30 months on the Kansas City Cardiomyopathy Questionnaire and 6-minute walk test. Also, the patients on Attruby increase in protein NT-proBNP was about half of the placebo group; this indicates that the treated patients had less heart failure than untreated patients after 30 months.

Attruby (acoramidis) is an oral prescription medicine used to treat heart problems due to cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). Attruby works by stabilizing transthyretin (TTR) to help reduce death and cardiovascular-related hospitalization and improve quality of life. Attruby mechanism of action is by binding to TTR at thyroxine binding sites, which slows the formation of harmful amyloid protein deposits in the heart, slowing disease progression. Attruby (acoramidis) is a near-complete (≥90%)  selective stabilizer of transthyretin (TTR), Attruby FDA approval was granted on November 22, 2024, it is indicated for treating the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular-related hospitalization and death. Attruby FDA approval was based on positive results from the ATTRibute-CM Phase 3 study, which showed a statistically significant treatment effect at 30 months on the Kansas City Cardiomyopathy Questionnaire and 6-minute walk test. Also, the patients on Attruby increase in protein NT-proBNP was about half of the placebo group; this indicates that the treated patients had less heart failure than untreated patients after 30 months.

Cytochrome C is contraindicated in conditions like Hypersensitivity to the drug.

Attruby side effects include diarrhea (11.6%) and upper abdominal pain (5.5%) in clinical trials.  The number of people who discontinued treatment due to side effects was 9.3% in the Attruby-treated group and 8.5% in the placebo-treated group. As with any medicine, hypersensitivity reactions are possible. Get emergency medical help if you have signs of an allergic reaction, such as hives, difficulty breathing, or swelling of your face, lips, tongue, or throat. This may not be all of the possible Attruby side effects. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

There are no warnings, serious side effects, or contraindications for this medicine.

There are no warnings, serious side effects, or contraindications for this medicine.

0.036 to 0.067 mg (0.052 (0.0515)) 12 hourly Ophthalmic — -

0.036 to 0.067 mg (0.052 (0.0515)) 12 hourly Opthalmic — -

No neonatal dosage information is recorded for this medicine yet.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines may affect how Attruby works, and Attruby may affect how some medicines work. Especially tell your healthcare provider if you take: UDP-glucuronosyltransferases (UGT) Inducers and Strong CYP3A Inducers Attruby is metabolized by UGT enzyme-mediated glucuronidation. Concomitant use of UGT inducers can potentially decrease acoramidis exposure. While acoramidis is not metabolized by CYP3A, strong CYP3A inducers can also induce UGT enzymes. Avoid concomitant use of ATTRUBY with UGT inducers and strong CYP3A inducers. Sensitive Cytochrome P450 2C9 (CYP2C9) substrates Attruby inhibits CYP2C9 and may result in an increase in CYP2C9 substrate concentrations when these drugs are both administered. Consider more frequent monitoring of patients for evidence of increased exposure (for example, signs of exposure-related toxicity) when Attruby is co-administered with sensitive CYP2C9 substrates.

IV Inj, Eye drops